The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,090.00
Bid: 12,088.00
Ask: 12,092.00
Change: 40.00 (0.33%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,124.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Euro zone yields dip, ECB says could reduce bonds buys

Thu, 08th Apr 2021 14:57

* Euro zone periphery govt bond yields http://tmsnrt.rs/2ii2Bqr
(Updates prices, adds U.S. Treasuries)

By Yoruk Bahceli and Julien Ponthus

AMSTERDAM/LONDON, April 8 (Reuters) - Euro zone bond yields
dipped on Thursday amid uncertainty over the bloc's COVID-19
vaccination programme, while minutes of the European Central
Bank's March meeting showed policymakers were ready to reduce
bond purchases if conditions allowed.

Pressure also came from Treasury yields which fell following
worse-than-expected U.S. job data while dovish Federal Reserve
minutes released on Wednesday showed the central bank was in no
rush to raise interest rates.

In late afternoon trading, safe-haven euro zone bond yields
ticked lower, with Germany's 10-year yield, the benchmark for
the bloc, losing around 1.2 basis point at -0.33%.

Italian 10-year bond yields were down 3 basis points at
0.67%, keeping the closely watched risk premium with Bunds at
about 100 basis points but below the four-week high it touched
on Wednesday.

Minutes of the ECB's March meeting published on Thursday
showed policymakers debated a smaller increase in bond purchases
and agreed to front-load the buying this quarter on condition it
could be cut later if conditions allowed.

Monthly bond buys under the ECB's 1.85 trillion-euro
Pandemic Emergency Purchase Programme (PEPP) jumped by over a
fifth last month, enough to stabilize nominal bond yields and
push inflation-adjusted yields back to their early-year lows.

The central bank ramped up buying of sovereign bonds after a
surge in U.S. Treasury yields lifted borrowing costs in the bloc
and threatened Europe's tentative recovery.

Sources told Reuters at the time that hawkish policymakers
were sceptical about increasing the purchases and some saw
rising nominal bond yields as a potentially welcome sign of
economic recovery.

Repeating the bank's overall standing guidance, ECB
President Christine Lagarde said on Thursday that the 1.85
trillion euros set aside may not have to be spent in full but
could also be increased depending on market conditions.

Lagarde also said that while the resurgent pandemic would
weigh on euro zone growth over the coming months, the recovery
was expected to pick up once lockdowns are lifted.

Lagarde's comments came as data showed euro zone producer
prices rose at an accelerated year-on-year pace in February as
the cost of energy and intermediate goods went up, underlining
expectations of faster consumer price growth in the coming
months.

Euro zone consumer inflation jumped in March to 1.3%, taking
another step higher in what is likely to be a temporary but
sharp climb that may put consumer price growth above the
European Central Bank's target of near 2% later this year.

The ECB has predicted the surge, warning that inflation may
even exceed its target by the close of the year, but has
promised to look past what it expects to be a temporary increase
in its policy decisions.

Worries about the rollout of COVID-19 vaccines and its
consequence for the European economy have risen after European
regulators found a potential link between AstraZeneca's vaccine
and reports of rare brain blood clots.

The setback for the vaccine, a key component of the bloc's
inoculation efforts, comes as the euro area grapples with a new
wave of the virus. Spanish regions tightened lockdowns on
Wednesday and Germany's chancellor supported a tougher lockdown.
(Reporting by Yoruk Bahceli and Julien Ponthus; editing by John
Stonestreet, Larry King and Andrew Heavens)

More News
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.